MCID: SCL009
MIFTS: 46

Sclerosing Cholangitis

Categories: Gastrointestinal diseases, Liver diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Sclerosing Cholangitis

MalaCards integrated aliases for Sclerosing Cholangitis:

Name: Sclerosing Cholangitis 11 58 75 14 16
Primary Sclerosing Cholangitis 71
Cholangitis, Sclerosing 71
Fibrosing Cholangitis 11

Classifications:

Orphanet: 58  
Rare hepatic diseases


External Ids:

Disease Ontology 11 DOID:14268
MeSH 43 D015209
SNOMED-CT 68 4032000
UMLS via Orphanet 72 C0008313
Orphanet 58 ORPHA447771
UMLS 71 C0008313 C0566602

Summaries for Sclerosing Cholangitis

MalaCards based summary: Sclerosing Cholangitis, also known as primary sclerosing cholangitis, is related to sclerosing cholangitis, neonatal and cholangitis, and has symptoms including icterus An important gene associated with Sclerosing Cholangitis is CLDN1 (Claudin 1), and among its related pathways/superpathways are Metabolism of steroids and Synthesis of bile acids and bile salts. The drugs Bezafibrate and Simvastatin have been mentioned in the context of this disorder. Affiliated tissues include liver, skin and t cells, and related phenotype is liver/biliary system.

Wikipedia: 75 Primary sclerosing cholangitis (PSC) is a long-term progressive disease of the liver and gallbladder... more...

Related Diseases for Sclerosing Cholangitis

Diseases in the Sclerosing Cholangitis family:

Cholangitis, Primary Sclerosing Secondary Sclerosing Cholangitis

Diseases related to Sclerosing Cholangitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 787)
# Related Disease Score Top Affiliating Genes
1 sclerosing cholangitis, neonatal 33.2 DCDC2 CLDN1
2 cholangitis 32.6 NR1H4 HP GPT GPBAR1 DCDC2 CLDN1
3 cholangitis, primary sclerosing 32.6 SLC10A2 SEPSECS NR1H4 MIRLET7I MIR222 MIR199A1
4 cholestasis 32.1 SLC10A2 NR1H4 GPT CYP7A1 ABCB4 ABCB11
5 autoimmune hepatitis 31.9 SEPSECS GPT ALB
6 obstructive jaundice 31.8 GPT ALB ABCB11
7 crohn's disease 31.8 ICOSLG HP CCR6 ALB
8 portal hypertension 31.7 NR1H4 MIR199A1 GPT CCR6 ALB
9 liver disease 31.5 SLC10A2 SEPSECS NR1H4 KRT19 GPT ALB
10 klatskin's tumor 31.5 KRT19 GPT ALB
11 bile duct cancer 31.4 MIR199A1 KRT19 GPT ALB
12 cholecystitis 31.4 HP GPT ALB ABCB4
13 choledocholithiasis 31.3 GPT ALB ABCB4 ABCB11
14 anemia, autoimmune hemolytic 31.3 ICOSLG HP CCR6
15 acute cholangitis 31.3 GPT ALB ABCB4
16 ascending cholangitis 31.3 GPT ALB ABCB4
17 esophageal varix 31.3 HP GPT ALB
18 autoimmune cholangitis 31.3 SEPSECS CCR6 ABCB4
19 primary biliary cholangitis 31.2 SLC10A2 SEPSECS NR1H4 MIR199A1 KRT19 ICOSLG
20 celiac disease 1 31.2 ICOSLG HP GPT CCR6 ALB
21 gallbladder cancer 31.2 MIR199A1 KRT19 GPT ALB
22 severe covid-19 31.2 GPT CCR6 ALB
23 viral hepatitis 31.1 SEPSECS KRT19 GPT ALB
24 pericholangitis 31.1 SLC10A2 NR1H4 GPT CYP7A1 ABCB4 ABCB11
25 acalculous cholecystitis 31.1 GPT ALB
26 deficiency anemia 31.0 ICOSLG HP GPT CCR6 ALB
27 colonic disease 31.0 MIR222 MIR199A1 ICOSLG CCR6
28 intrahepatic cholangiocarcinoma 31.0 MIR199A1 KRT19 ALB
29 chronic cholangitis 31.0 GPT ABCB4
30 bone disease 31.0 MIR222 MIR199A1 ICOSLG CCR6
31 viral infectious disease 31.0 MIR199A1 ICOSLG GPT CCR6
32 bile duct cysts 30.9 KRT19 GPT ALB ABCB4 ABCB11
33 intrahepatic cholestasis 30.9 SLC10A2 NR1H4 GPT ALB ABCB4 ABCB11
34 spondyloarthropathy 1 30.9 ICOSLG HP CCR6
35 gallbladder disease 30.9 NR1H4 MIR222 MIR199A1 GPT CCR6 ALB
36 respiratory failure 30.9 MIR199A1 GPT CCR6 ALB
37 cholelithiasis 30.9 NR1H4 HP GPT CYP7A1 ALB ABCB4
38 biliary atresia 30.8 SLC10A2 NR1H4 GPT ALB ABCB4 ABCB11
39 hypercholesterolemia, familial, 1 30.8 SLC10A2 NR1H4 GPT CYP7A1
40 bilirubin metabolic disorder 30.8 SLC10A2 NR1H4 HP GPT CYP7A1 ALB
41 intestinal disease 30.8 MIRLET7I MIR222 MIR199A1 ICOSLG CCR6
42 acute kidney failure 30.8 HP GPT ALB
43 suppurative cholangitis 30.7 SEPSECS GPT ALB ABCB4
44 immunoglobulin alpha deficiency 30.7 ICOSLG HP CCR6
45 hemochromatosis, type 1 30.6 MIR199A1 HP GPT ALB
46 non-alcoholic steatohepatitis 30.6 NR1H4 MIR199A1 GPT GPBAR1 CYP7A1 CCR6
47 alpha-1-antitrypsin deficiency 30.6 SEPSECS GPT ALB
48 exanthem 30.6 ICOSLG GPT CCR6 ALB
49 lymphatic system disease 30.5 MIRLET7I MIR222 MIR199A1 ICOSLG CCR6
50 extrahepatic cholestasis 30.5 SLC10A2 NR1H4 GPT CYP7A1 ABCB4 ABCB11

Graphical network of the top 20 diseases related to Sclerosing Cholangitis:



Diseases related to Sclerosing Cholangitis

Symptoms & Phenotypes for Sclerosing Cholangitis

UMLS symptoms related to Sclerosing Cholangitis:


icterus

MGI Mouse Phenotypes related to Sclerosing Cholangitis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 liver/biliary system MP:0005370 9.28 ABCB11 ABCB4 ALB CYP7A1 GPBAR1 HP

Drugs & Therapeutics for Sclerosing Cholangitis

Drugs for Sclerosing Cholangitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 75)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bezafibrate Approved, Investigational Phase 3 41859-67-0 39042
2
Simvastatin Approved Phase 3 79902-63-9 54454
3
Ursodeoxycholic acid Approved, Investigational Phase 2, Phase 3 128-13-2 31401
4
Clofibric Acid Phase 3 882-09-7 2797
5 Anticholesteremic Agents Phase 3
6 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 3
7
Mitomycin Approved Phase 2 50-07-7 5746
8
Curcumin Approved, Investigational Phase 1, Phase 2 458-37-7, 84765-67-3 969516
9
Cladribine Approved, Investigational Phase 2 4291-63-8 20279
10
Aldesleukin Approved Phase 2 110942-02-4
11
Sulfasalazine Approved Phase 2 599-79-1 5353980 5339 5359476
12
Thalidomide Approved, Investigational, Withdrawn Phase 2 50-35-1 5426
13
Fenofibrate Approved Phase 1, Phase 2 49562-28-9 3339
14
Isotretinoin Approved, Investigational, Nutraceutical Phase 2 302-79-4, 4759-48-2 5538 444795 5282379
15
Cenicriviroc Investigational Phase 2 497223-25-3 6320532 11285792
16
Seladelpar Investigational Phase 2 851528-79-5 11476297 11236126
17
Volixibat Experimental, Investigational Phase 2 1025216-57-2
18 Alkylating Agents Phase 2
19 Hormones Phase 2
20 Calcium, Dietary Phase 2
21 Immunoglobulins Phase 2
22 Antibodies Phase 2
23 Antiviral Agents Phase 2
24 Anti-Retroviral Agents Phase 2
25 Anti-HIV Agents Phase 2
26 Antibodies, Monoclonal Phase 2
27 2-chloro-3'-deoxyadenosine Phase 2 14485373
28 Interleukin-2 Phase 2
29 Analgesics Phase 2
30 Antirheumatic Agents Phase 2
31 Anti-Inflammatory Agents, Non-Steroidal Phase 2
32 Analgesics, Non-Narcotic Phase 2
33 Anti-Inflammatory Agents Phase 2
34 Bile Acids and Salts Phase 2
35 Antimetabolites Phase 1, Phase 2
36 Hypolipidemic Agents Phase 1, Phase 2
37 Lipid Regulating Agents Phase 1, Phase 2
38 Keratolytic Agents Phase 2
39 Dermatologic Agents Phase 2
40 Angiogenesis Inhibitors Phase 2
41 Immunosuppressive Agents Phase 2
42 Immunologic Factors Phase 2
43
Calcium Nutraceutical Phase 2 7440-70-2 271
44
Minocycline Approved, Investigational Phase 1 10118-90-8, 13614-98-7 54675783 5281021
45
Rifaximin Approved, Investigational Phase 1 80621-81-4 46783403 6436173
46
Erlotinib Approved, Investigational Phase 1 183319-69-9, 183321-74-6 176870
47
Budesonide Approved Phase 1 51333-22-3 5281004 40000 63006
48
Metronidazole Approved Phase 1 443-48-1, 69198-10-3 4173
49
Rituximab Approved Phase 1 174722-31-7
50
Lenalidomide Approved Phase 1 191732-72-6 216326

Interventional clinical trials:

(show top 50) (show all 114)
# Name Status NCT ID Phase Drugs
1 Evaluation of Effectiveness and Safety of Oral Vancomycin in Treatment of Primary Sclerosing Cholangitis. Unknown status NCT02605213 Phase 4 Vancomycin;Placebo
2 The Effect of Bezafibrate on Cholestatic Itch Unknown status NCT02701166 Phase 3 Bezafibrate;Placebo
3 Probiotics in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Disease- a Randomized Placebo-Controlled Cross-Over Trial Unknown status NCT00161148 Phase 3 Probiotics
4 Multicenter Randomized Trial Comparing Short-term Stenting Versus Balloon Dilatation for Dominant Strictures in Primary Sclerosing Cholangitis Unknown status NCT01398917 Phase 3
5 Treatment of Primary Sclerosing Cholangitis in Inflammatory Bowel Disease Patients With Oral Vancomycin by the Study of Its Antimicrobial and Immunomodulating Effects Completed NCT01802073 Phase 3 Oral Vancomycin
6 Digital SpyGlass Cholangioscopy Confirmed Common Bile Duct Stones Clearance Without Fluoroscopy Completed NCT02967926 Phase 3
7 Double-blind, Randomized, Placebo-controlled, Phase III Study Comparing norUrsodeoxycholic Acid Capsules With Placebo in the Treatment of Primary Sclerosing Cholangitis Recruiting NCT03872921 Phase 3 norUrsodeoxycholic Acid
8 Double Blind, Multicentric, Randomized, Placebo-controlled Trial, Evaluating the Efficacy of 24 Month of Bezafibrate in Primary Sclerosing Cholangitis With Persistent Cholestasis Despite Ursodeoxycholic Acid Therapy Recruiting NCT04309773 Phase 3 Bezafibrate (400mg) in addition to standard 15-20 mg/kg/jour UDCA therapy;Placebo of Bezafibrate in addition to standard UDCA therapy
9 A Prospective, Randomized, Multi-centered, Placebo-controlled Clinical Trial of Oral Vanycomycin in Adults With Primary Sclerosing Cholangitis Recruiting NCT03710122 Phase 2, Phase 3 Vancomycin
10 Effect of Simvastatin on the Prognosis of Primary Sclerosing Cholangitis (PSC); A Randomized, Double-blind, Placebo Controlled Multicenter Study Recruiting NCT04133792 Phase 3 Simvastatin 40mg;Placebo oral tablet
11 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Subjects With Primary Sclerosing Cholangitis Active, not recruiting NCT03890120 Phase 3 Cilofexor;Placebo
12 Multicentered Randomized Trial of High-dose Urso in Primary Sclerosing Cholangitis Terminated NCT00059202 Phase 2, Phase 3 Ursodeoxycholic Acid;Placebo
13 A Randomized, Global, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Vedolizumab IV for the Treatment of Primary Sclerosing Cholangitis, With Underlying Inflammatory Bowel Disease Withdrawn NCT03035058 Phase 3 Vedolizumab;Placebo
14 Phase 2 Study of Mitomycin C Therapy for Biliary Strictures in Patients With Primary Sclerosing Cholangitis Unknown status NCT01688024 Phase 2 Mitomycin C;Normal saline
15 A Pilot, Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of LUM001, an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTi), in Patients With Primary Sclerosing Cholangitis Completed NCT02061540 Phase 2 LUM001
16 A Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of NGM282 Administered for 12 Weeks in Patients With Primary Sclerosing Cholangitis Completed NCT02704364 Phase 2
17 Investigation of the Activity of Vidofludimus Calcium, a Novel, Orally Available, Small Molecule Inhibitor of Dihydroorotate Dehydrogenase, as a Treatment for Primary Sclerosing Cholangitis (PSC) Completed NCT03722576 Phase 2 Vidofludimus calcium
18 A Proof-of-Concept and Dose-Ranging Study Investigating the Efficacy and Safety of HTD1801 in Adult Subjects With Primary Sclerosing Cholangitis (PSC) Completed NCT03333928 Phase 2 HTD1801;Placebo
19 An Open-Label Pilot Study Evaluating the Safety and Efficacy of Curcumin in Patients With Primary Sclerosing Cholangitis Completed NCT02978339 Phase 1, Phase 2 Curcumin
20 PERSEUS: A Phase 2 Proof of Concept Study Investigating the Preliminary Efficacy and Safety of Cenicriviroc in Adult Subjects With Primary Sclerosing Cholangitis (PSC) Completed NCT02653625 Phase 2 Cenicriviroc 150 mg
21 A Phase 2, Randomized, Double Blind, Placebo Controlled, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of Seladelpar Administered for 24 Weeks in Adult Patients With Primary Sclerosing Cholangitis (PSC) Completed NCT04024813 Phase 2 Seladelpar;Placebo to match Seladelpar
22 A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase Like 2 (LOXL2) in Subjects With Primary Sclerosing Cholangitis (PSC) Completed NCT01672853 Phase 2
23 Fecal Microbiota Transplantation for the Treatment of Primary Sclerosing Cholangitis. Completed NCT02424175 Phase 1, Phase 2
24 Phase II Pilot Study of Cladribine (2-Chlorodeoxyadenosine; 2-CdA) for Early Stage Primary Sclerosing Cholangitis Completed NCT00004762 Phase 2 cladribine
25 A Single Arm, Two-stage, Multi-centre, Phase II Clinical Trial Investigating the Safety and Activity of the Use of BTT1023 Targeting Vascular Adhesion Protein (VAP-1), in the Treatment of Patients With Primary Sclerosing Cholangitis (PSC). Completed NCT02239211 Phase 2 BTT1023
26 A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding, Clinical Trial Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Primary Sclerosing Cholangitis Completed NCT02177136 Phase 2 Obeticholic Acid (OCA);Placebo
27 A Phase 2, Randomized, Double-Blind, Placebo Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Subjects With Primary Sclerosing Cholangitis Without Cirrhosis Completed NCT02943460 Phase 2 Cilofexor;Placebo to match cilofexor
28 Double-blind,Randomized, Placebo-controlled, Phase II Dose-finding Study Comparing Different Doses of Norursodeoxycholic Acid Capsules With Placebo in the Treatment of Primary Sclerosing Cholangitis Completed NCT01755507 Phase 2 norUDCA;Placebo
29 Induction of Regulatory t Cells by Low Dose IL2 in Autoimmune and Inflammatory Diseases: a Transnosographic Approach Completed NCT01988506 Phase 2 Interleukin 2
30 A Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Volixibat in the Treatment of Cholestatic Pruritus in Patients With Primary Sclerosing Cholangitis Recruiting NCT04663308 Phase 2 Volixibat;Placebo
31 A Randomized, Double-blind, Dose-ranging, Placebo-controlled, Phase 2a Evaluation of the Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Participants With Primary Sclerosing Cholangitis (PSC) and Suspected Liver Fibrosis (INTEGRIS-PSC) Recruiting NCT04480840 Phase 2 PLN-74809;Placebo
32 A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Clinical Trial Evaluating The Safety And Efficacy Of CM-101 In Subjects With Primary Sclerosing Cholangitis- The SPRING Study Recruiting NCT04595825 Phase 2
33 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP547 in Subjects With Cholestatic Pruritus Due to Primary Biliary Cholangitis or Primary Sclerosing Cholangitis Recruiting NCT05525520 Phase 2 EP547;Placebo
34 An Adaptive, Multicentre, Phase IIa, Multi-disease Trial Investigating the Safety & Activity of a Single Infusion of Selected Mesenchymal Stromal Cells in the Treatment of Patients With Primary Sclerosing Cholangitis & Autoimmune Hepatitis Recruiting NCT02997878 Phase 1, Phase 2
35 A Randomized, Placebo-controlled Pilot Study of Sulfasalazine for the Treatment of Primary Sclerosing Cholangitis (PSC) Recruiting NCT03561584 Phase 2 Sulfasalazine;Placebo
36 Intra-arterial Injection of Umbilical Cord Mesenchymal Stem Cells in Primary Sclerosing Cholangitis Active, not recruiting NCT03516006 Phase 1, Phase 2 UCMSC;UDCA
37 A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis (PSC). Not yet recruiting NCT05627362 Phase 2 Elafibranor 80 mg;Elafibranor 120 mg;Placebo Matched to Elafibranor 80 mg;Placebo Matched to Elafibranor 120 mg
38 An Open Label, Phase 2 Study to Evaluate the Effect of A3907 on Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Adults With Primary Sclerosing Cholangitis (PSC) Not yet recruiting NCT05642468 Phase 2 A3907
39 A Study of Oral Hymecromone to Treat Adolescents and Adults With Primary Sclerosing Cholangitis(HAAPS Study). Not yet recruiting NCT05295680 Phase 2 Hymecromone
40 An Efficacy Trial of Low Dose All-trans Retinoic Acid (ATRA) in Patients With Primary Sclerosing Cholangitis Terminated NCT03359174 Phase 2 All-trans retinoic acid
41 A Randomized, Open-label, Phase 2 Study to Evaluate Safety and Efficacy of DUR-928 in Subjects With Primary Sclerosing Cholangitis (PSC) Terminated NCT03394781 Phase 2 DUR-928
42 Open Label, Phase II Investigation of Thalidomide for the Treatment of Primary Sclerosing Cholangitis Terminated NCT00953615 Phase 2 Thalidomide
43 Pilot Study of Fenofibrate in Primary Sclerosing Cholangitis Terminated NCT01142323 Phase 1, Phase 2 fenofibrate
44 A Phase 2, Randomized, Double-Blind Study of HTD1801 vs Ursodeoxycholic Acid (UDCA) in Adolescents With Primary Sclerosing Cholangitis (PSC) Withdrawn NCT03678480 Phase 2 HTD1801;Ursodeoxycholic Acid
45 Primary Sclerosing Cholangitis: Value of Computerized Tomographic Cholangiography and Intraductal Volumetric Measurement in Determining the Prognosis Withdrawn NCT00588458 Phase 2
46 Open Label Pilot Study Evaluating Minocycline in Patients With Primary Sclerosing Cholangitis (PSC) Completed NCT00630942 Phase 1 Minocycline
47 A Pilot Study of Xifaxan in Patients With Primary Sclerosing Cholangitis Completed NCT01695174 Phase 1 Xifaxan
48 An Open Label Pilot Trial of Erlotinib (Tarceva) in Primary Sclerosing Cholangitis With Trisomy 7 Completed NCT00955149 Phase 1 Erlotinib (Tarceva)
49 Pilot Study of Budesonide for Patients With Primary Sclerosing Cholangitis Completed NCT00004842 Phase 1 budesonide
50 A Pilot Study to Characterize Bile Acid Metabolism and Dysbiosis in Primary Sclerosing Cholangitis Completed NCT02464020 Phase 1 Vancomycin

Search NIH Clinical Center for Sclerosing Cholangitis

Genetic Tests for Sclerosing Cholangitis

Anatomical Context for Sclerosing Cholangitis

Organs/tissues related to Sclerosing Cholangitis:

MalaCards : Liver, Skin, T Cells, Colon, Pancreas, Neutrophil, B Cells

Publications for Sclerosing Cholangitis

Articles related to Sclerosing Cholangitis:

(show top 50) (show all 6980)
# Title Authors PMID Year
1
Autoimmune conditions and pancreatic cancer risk in older American adults. 62
36059225 2023
2
A Case of Successful Management of Adult-Onset Linear IgA Bullous Disease With Sulfasalazine During the COVID-19 Pandemic. 62
36468952 2022
3
Risks of colorectal cancer and biliary cancer according to accompanied primary sclerosing cholangitis in Korean patients with ulcerative colitis: a nationwide population-based study. 62
36453007 2022
4
Optimal timing of liver transplantation for liver cirrhosis caused by sclerosing cholangitis in a patient with Langerhans cell histiocytosis: a case report. 62
36469185 2022
5
Development of a prognostic MRCP-score (DiStrict) for individuals with large-duct primary sclerosing cholangitis. 62
36444388 2022
6
Low prevalence of primary sclerosing cholangitis in patients with inflammatory bowel disease in India. 62
36453008 2022
7
Patient-Predicted Outcomes Are Associated with Quality of Life in Patients with Primary Sclerosing Cholangitis. 62
35347534 2022
8
Increased Risk of Non-conventional and Invisible Dysplasias in Patients with Primary Sclerosing Cholangitis and Inflammatory Bowel Disease. 62
35771958 2022
9
Practical Guide for Radiological Diagnosis of Primary and Secondary Sclerosing Cholangitis. 62
36462808 2022
10
Inflammatory type 2 conventional dendritic cells contribute to murine and human cholangitis. 62
35798133 2022
11
Inflammatory conditions play a role in recurrence of PSC after liver transplantation: An international multicentre study. 62
36426376 2022
12
Results of Intrahepatic Cholangiocarcinoma Resections: a Single-Center Analysis. 62
34989985 2022
13
Fenofibrate Downregulates NF-κB Signaling to Inhibit Pro-inflammatory Cytokine Secretion in Human THP-1 Macrophages and During Primary Biliary Cholangitis. 62
35838934 2022
14
Progressive cholestasis and associated sclerosing cholangitis are frequent complications of COVID-19 in patients with chronic liver disease. 62
35596929 2022
15
Secondary sclerosing cholangitis after COVID-19 pneumonia: a report of two cases and review of the literature. 62
35953614 2022
16
COVID-19-associated secondary sclerosing cholangitis - A case series of 4 patients. 62
36347499 2022
17
IgG4-related sclerosing cholangitis involving the gallbladder mimicking a hilar cholangiocarcinoma. 62
35272374 2022
18
Reducing relapse through maintenance steroid treatment can decrease the cancer risk in patients with IgG4-sclerosing cholangitis : based on a Japanese nationwide study. 62
36403136 2022
19
Relationship Between Stages of Ileal Pouch-Anal Anastomosis, Timing of Restoration of Fecal Continuity, and Pouchitis. 62
35246803 2022
20
Waitlist mortality in patients with autoimmune liver diseases. 62
35835366 2022
21
Loss of Apical Sodium Bile Acid Transporter Disrupts Bile Acid Circulation and Reduces Biliary Damage in Cholangitis. 62
36410025 2022
22
A common variant in the hepatobiliary phospholipid transporter ABCB4 modulates liver injury in PBC but not in PSC: prospective analysis in 867 patients. 62
36397154 2022
23
Recent advances in surveillance colonoscopy for dysplasia in inflammatory bowel disease. 62
36397275 2022
24
Gut-liver axis: Pathophysiological concepts and clinical implications. 62
36208625 2022
25
Lack of EGFR catalytic activity in hepatocytes improves liver regeneration following DDC-induced cholestatic injury by promoting a pro-restorative inflammatory response. 62
36148647 2022
26
Hepatic dry copper weight in paediatric autoimmune liver disease. 62
36332083 2022
27
Genetic link between rheumatoid arthritis and autoimmune liver diseases: A two-sample Mendelian randomization study. 62
36446255 2022
28
Chemoprevention of Colitis-Associated Dysplasia or Cancer in Inflammatory Bowel Disease. 62
35670121 2022
29
Microbial manipulation as therapy for primary sclerosing cholangitis. 62
36324251 2022
30
A Randomized, Dose-Finding, Proof-of-Concept Study of Berberine Ursodeoxycholate in Patients With Primary Sclerosing Cholangitis. 62
36327436 2022
31
A quantitative MRCP-derived score for medium-term outcome prediction in primary sclerosing cholangitis. 62
36357293 2022
32
Adenosquamous Carcinoma of Extrahepatic Bile Duct in Primary Sclerosing Cholangitis. 62
36028730 2022
33
Survey uncovering variations in the management of primary sclerosing cholangitis across Europe. 62
36164416 2022
34
Disease burden in primary sclerosing cholangitis in the Netherlands: A long-term follow-up study. 62
36328957 2022
35
The microbiota and the gut-liver axis in primary sclerosing cholangitis. 62
36352157 2022
36
Algebraic topology-based machine learning using MRI predicts outcomes in primary sclerosing cholangitis. 62
36396865 2022
37
The time is ripe for a randomized controlled trial of oral vancomycin in Primary Sclerosing Cholangitis. 62
36442726 2022
38
Cholangiocarcinoma cell proliferation is enhanced in primary sclerosing cholangitis: A role for IL-17A. 62
36346104 2022
39
PR3-ANCAs Detected by Third-Generation ELISA Predicts Severe Disease and Poor Survival in Primary Sclerosing Cholangitis. 62
36359524 2022
40
Prospective surveillance for cholangiocarcinoma in unselected individuals with primary sclerosing cholangitis. 62
36410555 2022
41
Quantitative magnetic resonance cholangiopancreatography metrics are associated with disease severity and outcomes in people with primary sclerosing cholangitis. 62
36277957 2022
42
Mesenchymal stem cells: A novel treatment option for primary sclerosing cholangitis. 62
36321586 2022
43
Fever of unknown origin due to Coxiella burnetii, an unexpected guest in primary sclerosing cholangitis. 62
36371385 2022
44
Good outcomes of living donor liver transplant in primary sclerosing cholangitis: an experience from North India. 62
36376772 2022
45
Ursodeoxycholic acid is associated with improved long-term outcome in patients with primary sclerosing cholangitis. 62
36068441 2022
46
Genetic alterations during the neoplastic cascade towards cholangiocarcinoma in primary sclerosing cholangitis. 62
35897137 2022
47
Suppression of bile acid synthesis as a tipping point in the disease course of primary sclerosing cholangitis. 62
36176935 2022
48
Berberine Ursodeoxycholate for the Treatment of Primary Sclerosing Cholangitis: The Search for the Elusive Pharmacologic Holy Grail Will Need to Continue. 62
36327435 2022
49
Safety and efficacy of switching to pemafibrate from bezafibrate in patients with chronic liver disease. 62
36378065 2022
50
Symptom Classes in Decompensated Liver Disease. 62
34813941 2022

Variations for Sclerosing Cholangitis

Expression for Sclerosing Cholangitis

Search GEO for disease gene expression data for Sclerosing Cholangitis.

Pathways for Sclerosing Cholangitis

GO Terms for Sclerosing Cholangitis

Cellular components related to Sclerosing Cholangitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 intercellular canaliculus GO:0046581 8.92 ABCB4 ABCB11

Biological processes related to Sclerosing Cholangitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 bile acid and bile salt transport GO:0015721 9.63 SLC10A2 CYP7A1 ABCB11
2 regulation of bile acid biosynthetic process GO:0070857 9.56 NR1H4 CYP7A1
3 bile acid signaling pathway GO:0038183 9.43 NR1H4 CYP7A1 ABCB11
4 cellular response to bile acid GO:1903413 9.1 NR1H4 GPBAR1 ABCB4

Molecular functions related to Sclerosing Cholangitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA base-pairing translational repressor activity GO:1903231 9.26 MIRLET7I MIR222 MIR199A1 MIR191
2 bile acid receptor activity GO:0038181 8.92 NR1H4 GPBAR1

Sources for Sclerosing Cholangitis

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....